Refine
Has Fulltext
- yes (52)
Is part of the Bibliography
- yes (52)
Year of publication
Document Type
Language
- English (52) (remove)
Keywords
- Toxikologie (32)
- Adenosine receptors (8)
- Adenosinrezeptor (5)
- Adenylate cyclase (4)
- G proteins (4)
- Pharmakologie (4)
- signal transduction (3)
- A1 adenosine receptors (2)
- Adenosin (2)
- G-protein (2)
- N-formyl peptides (2)
- Pharmazie (2)
- Radioligand binding (2)
- adenosine receptors (2)
- mast cells (2)
- membrane skeleton (2)
- (Rat brain membrane) (1)
- A(2B) receptors (1)
- A1 (1)
- A1 Adenosine receptors (1)
- A<sub>2</sub> Adenosine receptor (1)
- A\(_{2A}\) adenosine receptor antagonist (1)
- Adenosine receptor (1)
- Adenosine receptor antagonists (1)
- Atria (1)
- Barbiturat (1)
- Barbiturates (1)
- Chemotactic receptors (1)
- Cyclic AMP (1)
- Dermatologie (1)
- GABA-receptor complex (1)
- Human platelets (1)
- Immunologie (1)
- Ischemia/reperfusion (1)
- K + -channels (1)
- LTB4 receptor (1)
- Leukocyte/endothelium interaction (1)
- Lung (1)
- Mastzelle (1)
- Microcirculation (1)
- Molekularpharmakologie (1)
- N1E 115 cells (1)
- Niere (1)
- Phosphodiesterase (1)
- Photoaffinity labelling (1)
- Radiation inactivation (1)
- Radioligand binding - 86Rb + -efflux (1)
- Radioligands (1)
- Radioligauds (1)
- Ratte (1)
- Species differences (1)
- Target size (1)
- Theophylline (1)
- Venerologie (1)
- Xanthines (1)
- [3H]PIA binding (1)
- actin (1)
- adenosine (1)
- adenosine 3',5'-cyclic monophosphate (1)
- adenylate cyclase (1)
- agonists (1)
- antagonists (1)
- anti-Parkinson agents (1)
- anti-inflammatory agents (1)
- atopic eczema (1)
- barbiturates (1)
- binding affinity (1)
- brain membranes (1)
- calcium (1)
- chalcone (1)
- chemotactic receptors (1)
- chemotaxis (1)
- classification (1)
- coated vesicles (1)
- coumarin (1)
- cytoskeleton (1)
- desensitization (1)
- docking (1)
- drug (1)
- formyl peptides (1)
- gastrointestinal cancer (1)
- hA<sub>3</sub>AR (1)
- histamine release (1)
- human A(3) (1)
- human lung (1)
- indolylpyrimidylpiperazines (1)
- international union (1)
- molecular modeling (1)
- neurodegenerative diseases (1)
- neutrophils (1)
- partial agonists (1)
- phosphoinositides (1)
- photoaffinity labelling (1)
- potent (1)
- protein-coupled receptors (1)
- psoriasis (1)
- purine derivatives (1)
- radioligand (1)
- rat brain membranes (1)
- receptor binding (1)
- receptor solubilization (1)
- receptor-G protein coupling (1)
- receptor-G protein coupling. (1)
- receptors (1)
- solubilization (1)
- subtypes (1)
- targets (1)
- triazolotriazine derivatives (1)
Institute
Adenosine receptor ligands: coumarin−chalcone hybrids as modulating agents on the activity of hARs
(2020)
Adenosine receptors (ARs) play an important role in neurological and psychiatric disorders such as Alzheimer's disease, Parkinson's disease, epilepsy and schizophrenia. The different subtypes of ARs and the knowledge on their densities and status are important for understanding the mechanisms underlying the pathogenesis of diseases and for developing new therapeutics. Looking for new scaffolds for selective AR ligands, coumarin–chalcone hybrids were synthesized (compounds 1–8) and screened in radioligand binding (hA\(_1\), hA\(_{2A}\) and hA\(_3\)) and adenylyl cyclase (hA\(_{2B}\)) assays in order to evaluate their affinity for the four human AR subtypes (hARs). Coumarin–chalcone hybrid has been established as a new scaffold suitable for the development of potent and selective ligands for hA\(_1\) or hA\(_3\) subtypes. In general, hydroxy-substituted hybrids showed some affinity for the hA\(_1\), while the methoxy counterparts were selective for the hA\(_3\). The most potent hA\(_1\) ligand was compound 7 (K\(_i\) = 17.7 µM), whereas compound 4 was the most potent ligand for hA\(_3\) (K\(_i\) = 2.49 µM). In addition, docking studies with hA\(_1\) and hA\(_3\) homology models were established to analyze the structure–function relationships. Results showed that the different residues located on the protein binding pocket could play an important role in ligand selectivity.